Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Subsequent Event

Subsequent Event	3 Months Ended
Mar. 31, 2022
Subsequent Event
12. Subsequent Events	12. Subsequent Event On April 25, 2022, the Company closed a private placement of 898,585 shares of its common stock, pre-funded warrants to purchase 2,875,000 shares of common stock (the “Pre-Funded Warrant”) and warrants to purchase up to 3,773,585 shares of common stock at an exercise price of $1.325 per share (the “Common Warrant”) for gross proceeds of $5.0 million. The Common Warrant related to this private placement will expire five years from the date the resale Form S-1 is declared effective, which was on May 13, 2022.

Subsequent Event

3 Months Ended

Mar. 31, 2022

12. Subsequent Event

On April 25, 2022, the Company closed a private placement of 898,585 shares of its common stock, pre-funded warrants to purchase 2,875,000 shares of common stock (the “Pre-Funded Warrant”) and warrants to purchase up to 3,773,585 shares of common stock at an exercise price of $1.325 per share (the “Common Warrant”) for gross proceeds of $5.0 million. The Common Warrant related to this private placement will expire five years from the date the resale Form S-1 is declared effective, which was on May 13, 2022.